Literatur
Carter HB, Albertsen PC, Barry MJ et al (2013) Early detection of prostate cancer: AUA Guideline. J Urol 190:419–426
Oelke M, Bachmann A, Descazeaud A et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64:118–140
Thompson IM Jr, Goodman PJ, Tangen CM et al (2013) Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 369:603–610
Traish AM, Hassani J, Guay AT et al (2011) Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sexual Med 8:872–884
Wilt TJ, Macdonald R, Hagerty K et al (2008) Five-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database Syst Rev:CD007091
Einhaltung ethischer Richtlinien
Interessenkonflikt. M.S. Michel, S. Nitschmann und J. von Hardenberg geben an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Michel, M., Nitschmann, S. & von Hardenberg, J. Prävention des Prostatakarzinoms. Internist 55, 981–982 (2014). https://doi.org/10.1007/s00108-014-3544-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-014-3544-4